JP2022540877A5 - - Google Patents

Info

Publication number
JP2022540877A5
JP2022540877A5 JP2022502075A JP2022502075A JP2022540877A5 JP 2022540877 A5 JP2022540877 A5 JP 2022540877A5 JP 2022502075 A JP2022502075 A JP 2022502075A JP 2022502075 A JP2022502075 A JP 2022502075A JP 2022540877 A5 JP2022540877 A5 JP 2022540877A5
Authority
JP
Japan
Prior art keywords
immunotoxin
amino acid
cx3cr1
sequence
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022502075A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540877A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/067785 external-priority patent/WO2021008840A1/en
Publication of JP2022540877A publication Critical patent/JP2022540877A/ja
Publication of JP2022540877A5 publication Critical patent/JP2022540877A5/ja
Pending legal-status Critical Current

Links

JP2022502075A 2019-07-12 2020-06-25 Cmv感染に関連する疾患の治療のための融合毒素タンパク質 Pending JP2022540877A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19186000 2019-07-12
EP19186000.6 2019-07-12
PCT/EP2020/067785 WO2021008840A1 (en) 2019-07-12 2020-06-25 Fusion toxin proteins for treatment of diseases related to cmv infections

Publications (2)

Publication Number Publication Date
JP2022540877A JP2022540877A (ja) 2022-09-20
JP2022540877A5 true JP2022540877A5 (https=) 2023-06-12

Family

ID=67437717

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502075A Pending JP2022540877A (ja) 2019-07-12 2020-06-25 Cmv感染に関連する疾患の治療のための融合毒素タンパク質

Country Status (10)

Country Link
US (1) US20220281933A1 (https=)
EP (1) EP3997107A1 (https=)
JP (1) JP2022540877A (https=)
KR (1) KR20220032610A (https=)
CN (1) CN114206944A (https=)
AU (1) AU2020312560A1 (https=)
BR (1) BR112022000417A2 (https=)
CA (1) CA3146798A1 (https=)
MX (1) MX2022000433A (https=)
WO (1) WO2021008840A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2603166A (en) * 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
EP4301394A1 (en) * 2021-03-03 2024-01-10 Synklino ApS Compositions for ex vivo organ care

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018954A2 (en) * 2000-08-30 2002-03-07 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
CA2437201C (en) * 2001-02-02 2008-11-18 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
EP2038302B1 (en) * 2006-07-03 2012-10-24 INAGEN ApS Immunotoxins for the treatment of diseases related to cmv infection
WO2010070394A1 (en) * 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製cmv
EP3262063B1 (en) * 2015-02-26 2021-09-22 Var2 Pharmaceuticals ApS Immunotherapeutic targeting of placental-like chondroitin sulfate using chimeric antigen receptors (cars) and immunotherapeutic targeting of cancer using cars with split-protein binding systems
US10849960B2 (en) * 2017-09-08 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer

Similar Documents

Publication Publication Date Title
ES2290241T3 (es) Anticuerpos monoclonales contra el receptor de interferon, con actividad neutralizadora contra el interferon de tipo i.
JP2023518596A5 (https=)
US8349326B2 (en) Methods and systems for multi-antibody therapies
JP2010512792A5 (https=)
CN110740754A (zh) 一种抗间皮素抗体及其抗体药物缀合物
JP2014519852A5 (https=)
US11883503B2 (en) Methods and compositions for cancer treatment
JP2023538422A5 (https=)
JP2023528207A5 (https=)
JP2022540877A5 (https=)
JP2024511131A5 (https=)
JP2017515473A5 (https=)
JP2024535925A5 (https=)
WO2015143581A1 (zh) 靶特异性双突变体融合蛋白质及其制备工艺
JP2019531100A5 (https=)
JP2022530068A5 (https=)
CN111378049A (zh) 抗肿瘤靶向融合蛋白、其偶联物及用途
JP2019527238A (ja) 薬物送達のための抗体融合タンパク質
JP2024516320A5 (https=)
TWI857985B (zh) 胜肽之結合物及其製造方法
RU2022103314A (ru) Слитые белки-токсины для лечения заболеваний, связанных с инфекциями cmv
KR101946779B1 (ko) 마이코플라스마 중화 에피토프 및 이에 대한 항체
EP2909235B1 (en) Polypeptides specifically binding to il-23
RU2010107608A (ru) Гены и белки brachyspira hyodysenteriae и их применение
CN100443503C (zh) 人源化ctla-4单链抗体与人穿孔素通道形成肽p34的重组免疫毒素